PROCEPT BioRobotics (PRCT) Expected to Post Earnings on Tuesday

PROCEPT BioRobotics (NASDAQ:PRCT) will likely be announcing its Q2 2026 results before the market opens on Tuesday, August 4th. Analysts expect PROCEPT BioRobotics to announce earnings of ($0.46) per share and revenue of $92.7710 million for the quarter. Investors are encouraged to explore the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 4:30 PM ET.

PROCEPT BioRobotics (NASDAQ:PRCT) last announced its quarterly earnings data on Wednesday, April 29th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.01). PROCEPT BioRobotics had a negative return on equity of 27.70% and a negative net margin of 31.82%.The business had revenue of $83.13 million during the quarter, compared to analysts’ expectations of $80.52 million. During the same period in the prior year, the company posted ($0.45) earnings per share. The firm’s revenue was up 20.1% on a year-over-year basis. On average, analysts expect PROCEPT BioRobotics to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

PROCEPT BioRobotics Trading Up 3.4%

Shares of NASDAQ PRCT opened at $18.62 on Friday. The company has a current ratio of 6.73, a quick ratio of 5.51 and a debt-to-equity ratio of 0.15. PROCEPT BioRobotics has a one year low of $16.67 and a one year high of $51.38. The business has a 50-day moving average price of $22.39 and a two-hundred day moving average price of $25.19. The firm has a market capitalization of $1.06 billion, a PE ratio of -10.23 and a beta of 0.87.

More PROCEPT BioRobotics News

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Neutral Sentiment: Investors who purchased PROCEPT shares between February 28, 2024, and February 25, 2026, have until September 22, 2026, to seek appointment as lead plaintiff in the pending class action. The notices are procedural and do not represent a court finding of wrongdoing. Deadline Alert: Procept BioRobotics Corporation Shareholders
• Negative Sentiment: The core allegations involve repeated underperformance in unit and handpiece sales, late-quarter bulk discounts, excess customer inventory, and sales being pulled forward. Plaintiffs allege these practices may have inflated recurring-revenue metrics and that the risks were not adequately disclosed. PROCEPT Faces Securities Class Action Amid Sales Pull-In Concerns
• Negative Sentiment: The unusually high volume of nearly identical law-firm announcements increases the visibility of the litigation and could weigh on the stock through potential legal costs, reputational damage, and uncertainty regarding the sustainability of demand and future revenue growth. PROCEPT Securities Fraud Class Action and Inventory Issues
• Negative Sentiment: UBS reportedly lowered its rating on PRCT to “Neutral,” adding to the cautious backdrop surrounding the company and its sales outlook. PROCEPT Rating Lowered to Neutral at UBS

Institutional Investors Weigh In On PROCEPT BioRobotics

A number of large investors have recently bought and sold shares of PRCT. Alliancebernstein L.P. raised its holdings in PROCEPT BioRobotics by 58.6% during the third quarter. Alliancebernstein L.P. now owns 3,419,784 shares of the company’s stock valued at $122,052,000 after buying an additional 1,262,928 shares in the last quarter. T. Rowe Price Investment Management Inc. lifted its position in shares of PROCEPT BioRobotics by 59.4% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,271,408 shares of the company’s stock worth $102,919,000 after buying an additional 1,218,815 shares during the last quarter. Mackenzie Financial Corp boosted its stake in shares of PROCEPT BioRobotics by 8.2% during the 4th quarter. Mackenzie Financial Corp now owns 1,573,405 shares of the company’s stock worth $49,512,000 after acquiring an additional 118,971 shares in the last quarter. Artisan Partners Limited Partnership boosted its stake in shares of PROCEPT BioRobotics by 11.4% during the 4th quarter. Artisan Partners Limited Partnership now owns 1,520,700 shares of the company’s stock worth $47,841,000 after acquiring an additional 155,601 shares in the last quarter. Finally, State Street Corp increased its holdings in shares of PROCEPT BioRobotics by 12.4% during the 4th quarter. State Street Corp now owns 1,489,029 shares of the company’s stock valued at $46,845,000 after acquiring an additional 164,358 shares during the last quarter. 89.46% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on PRCT. Weiss Ratings reiterated a “sell (e+)” rating on shares of PROCEPT BioRobotics in a report on Friday, July 17th. Citigroup downgraded shares of PROCEPT BioRobotics to a “hold” rating in a research report on Thursday, July 2nd. Piper Sandler reiterated an “overweight” rating and issued a $35.00 price objective (up from $28.00) on shares of PROCEPT BioRobotics in a research note on Thursday, April 30th. Wall Street Zen upgraded shares of PROCEPT BioRobotics from a “strong sell” rating to a “sell” rating in a research report on Saturday, April 25th. Finally, Leerink Partners lowered shares of PROCEPT BioRobotics from an “outperform” rating to a “market perform” rating and decreased their target price for the company from $31.00 to $29.00 in a research note on Thursday, June 11th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, eight have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, PROCEPT BioRobotics currently has an average rating of “Hold” and an average price target of $33.45.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.